Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Alberto Chiappori,Charles C. Williams,Ben C. Creelan,Tawee Tanvetyanon,Jhanelle E. Gray,Eric B. Haura,Ram Thapa,Dung-Tsa Chen,Amer A. Beg,Theresa A. Boyle,Jennifer Bendiske,Erick Morris,Aiyang Tao,Felipe K. Hurtado,Luigi Manenti,Julio Castro,Scott Antonia

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

2018

Alberto Chiappori
Charles C. Williams
Ben C. Creelan
Tawee Tanvetyanon
Jhanelle E. Gray
Eric B. Haura
Ram Thapa
Dung-Tsa Chen
Amer A. Beg
Theresa A. Boyle
Jennifer Bendiske
Erick Morris
Aiyang Tao
Felipe K. Hurtado
Luigi Manenti
Julio Castro
Scott Antonia

9089Background: ATP is catabolized to adenosine in the tumor microenvironment, leading to excess adenosine and immunosuppressive effects via immune checkpoint protein adenosine 2A receptor (A2AR). ...

Keywords:

Antagonist
Physical therapy
Immunotherapy
Cancer research
Medicine
oral immunotherapy
in patient
Receptor
Adenosine
Immune checkpoint
Tumor microenvironment
Pathology
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations